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In this thesis we explored the role of heparan sulfate proteoglycans 
(HSPGs) in renal inflammation, with a focus on leukocyte migration and comple-
ment activation. We experimentally showed the crucial role of (sub-)endothe-
lial HSPGs on renal leukocyte infiltration in diabetic kidney disease, ischemia/
reperfusion (I/R) and renal transplantation. In a rat renal transplantation model, 
we demonstrated that treatment with heparin (derivatives) doesn’t lead to im-
proved graft function, despite reduced inflammation, most likely due to increased 
lymphatic migration of antigen presenting cells as a result of heparin (deriva-
tive) treatment. In the second part of the thesis we showed HSPGs to function 
as docking platforms for complement components. We showed that binding of 
the alternative complement pathway component properdin to tubular epithelial 
cells is largely syndecan-1/heparan sulfate dependent, but, in contrast to other 
sites, does not require initial C3b binding and efficiently initiates the alternative 
route of complement. We furthermore showed that bound properdin can be dis-
sociated from cellular heparan sulfate by tick protein SALP20, a powerful inhibi-
tor of the alternative pathway of complement. Moreover, we demonstrated the 
potential of heparan sulfate (HS) and heparin derivatives to specifically inhibit 
the lectin pathway of complement via MASP enzyme inhibition and that HSPGs 
might dock the MBL/MASP complex. 
 About a decade ago, Wang and colleagues elegantly showed that en-
dothelial HSPGs are major contributors to leukocyte recruitment. It was shown 
that endothelial HSPGs are ligands for L-selectin and play a role in chemokine 
presentation to high affinity receptors on leukocytes (1). The group of Wang, we 
and others subsequently explored the role of endothelial HSPGs in various dis-
eases concluding that the interaction between endothelial HSPGs,  L-selectin and 
chemokines can be a target for anti-inflammatory treatment (2-5). In chapter 
3 we showed, in line with these results, that glomerular and tubulo-interstitial 
leukocyte recruitment in experimental diabetic kidney disease is attenuated by 
endothelial deficient in sulfated HSPGs. Moreover and more importantly, we 
showed a protective effect of under sulfated endothelial HSPGs on renal fibrosis, 
which has not been shown before. The relationship between HSPGs and fibrosis 
has been known for quite some time (6) and our group already demonstrated 
that HSPG expression is changed under pro-fibrotic circumstances (7). In line with 
these findings, Alhasan and colleagues showed that fibrosis in chronic transplant 
dysfunction is accompanied by an increased expression of 6-O sulfated heparan 
sulfates on tubular epithelium and that 6-O sulfation increases the binding of 
FGF-2 to tubular epithelial cells, leading to increased pro-fibrotic signaling (8). Al-
though these studies focused primarily on the effect of HSPG changes in epithe-
lial cells, we showed in chapter 3 that under sulfated endothelial HSPGs prevent 
glomerulosclerosis and interstitial fibrosis. Whether endothelial HSPGs influence 
the fibrotic process directly or indirectly via prevention of inflammatory leuko-
cyte influx we can only speculate on. It is known that inflammation and fibrosis 
are closely linked to each other (9). However a direct effect of under sulfated 
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chemokine signaling to myofibroblasts or disruption of the signaling pathways of 
endothelial to mesenchymal transition could also contribute to the effect seen. 
Further research on how under sulfated endothelial HSPGs contribute to an an-
ti-fibrotic effect could be interesting both from a clinical and mechanistic point of 
view.
In the research field of proteoglycans and inflammation there is some 
controversy on the question whether endothelial basement membrane (BM) or 
endothelial surface layer (ESL) HSPGs are the major contributors to leukocyte 
recruitment. From the data in chapter 3, and other publications, it becomes 
clear that endothelial HSPGs are involved in leukocyte recruitment. However 
since endothelial cells produce both the ESL and in part the BM HSPGs, no firm 
conclusions could be drawn from these experiments on the localization of in-
volved endothelial HSPG (2,3). Therefore in chapter 4 we studied in vitro and in 
vivo the effect of collagen XV and XVIII deficiency on leukocyte recruitment in 
an ischemia reperfusion (I/R) model. Collagen XV and XVIII are collagen/HSPG 
hybrid molecules which are present in the abluminal BM zone of blood vessels. 
We demonstrated that collagen XV and XVIII are essential for macrophage and 
neutrophil recruitment, indicating that these BM HSPGs play a dominant role 
in leukocyte transmigration. It is thought that ESL HSPGs are primarily involved 
in binding of L-selectin and presenting chemokines to high affinity receptors on 
leukocytes. It has however also been shown that deficiency of syndecan-1, an ESL 
HSPGs, results in increased leukocyte transmigration (10). Therefore a second 
theory constitutes that the ESL under normal circumstances is covering E- and 
P-selectin and adhesion molecules such as ICAM-1 and VCAM-1 on the endo-
thelial cell, but degradation of the ESL under inflammatory stimuli reveals these 
selectins and CAMs, thereby aiding in leukocyte transmigration. It is for example 
thought that the anti-inflammatory effect of sulodexide, a mixture of heparan 
sulfate and dermatan sulfate, is partially because of the inhibition of hepara-
nase-1, thereby inhibiting the degradation of the ESL (11,12). The roles of the ESL 
in leukocyte recruitment have recently been nicely summarized by Marki et. al. 
(13). The contribution of BM HSPGs is thought to be more in terms of chemokine 
gradient stabilization over the entire width of the basement membrane, which is 
essential to overcome the physical BM barrier for leukocyte extravasation. Thus, 
in chapter 4 we showed that deficiency of the endothelial BM for HSPGs can 
obliterate the transmigration of neutrophils and macrophages. This finding is in 
line with experiments of Celie and colleagues who showed that under inflamma-
tory circumstances, BM HSPGs convert into major chemokine, but also L-selectin 
binding entities. This indicates that BM HSPGs might be more than just chemo-
kine presenters in leukocyte transmigration (4). Comprehensive models should 
be developed to study the exact contribution of ESL and BM HSPGs in leukocyte 
recruitment. 
Knockout studies for endothelial and BM HSPGs as shown in chapter 3 
& 4 suggest that the interaction between HSPGs and chemokines could be a tar-
get for therapy in inflammatory renal diseases. Targeting the chemokine - HSPG 
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interaction to reduce inflammation has been tested in various experimental 
models using different methods. Gschwandtner and colleagues used a CXCL8 
mutant with high affinity for GAGs but without signaling activity in a model for 
lung fibrosis, uveitis and urinary tract infection. In all experimental models the 
treatment with the decoy protein resulted in reduced leukocyte transmigration 
(14). In experimental renal chronic transplant dysfunction, treatment with low 
molecular weight reviparin resulted in reduced leukocyte accumulation in the in-
terstitium and improved graft function compared to controls (15). Trials to target 
the chemokine HSPG interaction in humans have been undertaken by targeting 
MCP-1. It has been shown in a phase II clinical trial that treatment with a MCP-
1 neutralizing spiegelmer (emapticap pegol) can reduce the albumin creatinine 
ratio in diabetic nephropathy patients (16). These positive results in clinical trials 
open the opportunity to investigate whether the chemokine HSPG interaction is 
a viable target in other inflammatory diseases as well.
 In chapter 5 we treated allografted rats with heparin and two heparin 
derivatives to interrupt the chemokine/HSPGs interaction and subsequently re-
duce leukocyte migration in this model for chronic transplant dysfunction. It had 
already been shown that heparin derivatives like reviparin could reduce leuko-
cyte migration and allograft dysfunction (15). However these studies were done 
with anti-coagulant heparin derivatives, which can be a disadvantageous feature 
in anti-inflammatory treatment when anti-coagulation is clinically undesirable. 
Therefore, in chapter 5, we included two heparin derivatives lacking anti-coagu-
lant action. One of the non-anti-coagulant heparins, glycol-split heparin, showed 
a reduction in leukocyte accumulation in the interstitium, however, failed to im-
prove graft function. To the contrary, treatment with glycol-split heparin seemed 
to reduce graft function, although not significantly. We showed in chapter 5 
that this is related to increased antigen presenting cell migration towards the 
lymphatic system. Migration of antigen presenting cells over the lymphatic en-
dothelium is, like vascular leukocyte migration, chemokine gradient mediated. 
Two majorly involved chemokines in this process are CCL19 and CCL21. Of the 
latter we showed that it can bind glycol-split heparin with a higher affinity than 
perlecan, a major constituent of the (lymph-) endothelial BM and a stabilizer of 
the chemokine gradient. Together with literature showing that CCL21 binding to 
glycosaminoglycans (GAGs) results in oligomerization, leading to increased func-
tionality of CCL21 (17), we conclude that the reduction in graft function in gly-
col-split heparin treated animals may be  due to an increased antigen presenting 
cells migration towards the lymphatic system. This increased migration can then 
lead to increased antigen presentation in lymph nodes resulting in a stronger al-
lograft response by the acquired immune system. Glycol-split heparin differs sig-
nificantly from the LMW heparin reviparin in length and molecular flexibility. This 
could explain the different results in our study compared to other studies using 
heparin (derivatives) in inflammatory models. The stimulatory effect on lymphat-
ic migration of glycol-split heparin is disadvantageous in treating chronic trans-
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can be of interest to stimulate antigen presenting cell migration to strengthen the 
acquired immune response against malignant cells. Therefore stimulating APC 
migration using heparin derivatives could increase the response to therapy (18).
 Since the results from chapter 5 show that high affinity for multiple 
chemokines can lead to unwanted effects, it can be concluded that specific af-
finity for one target in the inflammatory cascade should be an important fea-
ture of GAG based anti-inflammatory agents. For the use of GAGs in targeting 
the chemokine HSPG interaction, a library of GAGs should be tested for affinity 
for multiple chemokines involved, as has been done for the complement system 
in chapter 8, to prevent unwanted effects as seen in chapter 5. Thereafter the 
effect of GAG binding on chemokines should be thoroughly investigated since 
most GAG/chemokine interactions facilitate oligomerization, increasing their ef-
fectiveness as has been demonstrated in vivo (19,20). It might be interesting to 
test whether GAGs can inhibit the oligomerization of chemokines. Small heparin 
fragments, as have been shown to be specific and functional in chapter 8, might 
be a suitable candidate to bind the GAG binding epitope on chemokines, without 
stimulating oligomerization. It has e.g. been shown in vitro that heparin tetra-
saccharides have an inhibitory effect on the interaction between CCL5 and CCR1 
(21). Other options can be to target leukocyte entry from the vasculature via the 
chemokine/HSPG interaction. Targeting chemokines using monoclonal antibod-
ies, e.g. against MCP-1, has been discussed before in this chapter. Studies using 
siRNA to reduce GAG sulfation, via the inhibition of the transcription of sulfo-
transferases, have shown to reduce macrophage influx and improve respiratory 
function in elastase induce pulmonary emphysema (22). Concluding from chap-
ter 2, 3, 4 & 5, we think that targeting the chemokine/HSPG interaction can by a 
viable target in renal inflammatory mechanisms. Multiple methods to target this 
interaction have been shown to be effective in different experimental models. 
 One of the interesting findings from chapter 5 is the ability to influence 
the effectiveness of lymphatic chemokines and thereby increase lymphatic mi-
gration of leukocytes. In chapter 5 we unfortunately showed an increase in the 
lymphatic leukocyte migration while in transplantation a reduction in lymphatic 
leukocyte migration could be beneficial for the patient. Inhibition of the CCL21/
CCR7 signaling has already been shown to improve graft function in corneal 
transplantation, by reducing dendritic cell migration to the draining lymph node 
by treatment with a CCR7 blocking agent (23). Whether an inhibiting effect on 
the CCL21/CCR7 axis can be repeated by a GAG based treatment is unknown. 
Heparin treatment of CCR7 carrying leukocytes did not influence migration over 
high endothelial venules (24). Targeting CCL21 with unfractionated heparins to 
reduce lymphatic leukocyte migration has been proven difficult in chapter 5. 
Literature shows that binding of heparin to CCL21 induces oligomerization and 
therefore increased function of CCL21 (25). Although it has been shown in vitro 
that heparin can also inhibit the function of CCL21 and reduce lymphocyte trans-
migration across high endothelial venules (24). This indicates that there might be 
possibilities for GAG based treatment in lymphatic leukocyte migration; however 
172
Chapter 9
the exact influence of heparin (derivative) binding on CCL21 effectiveness should 
be studied first. 
Many anti-inflammatory therapeutics released in the past few years like 
eculizumab and golimumab are monoclonal antibodies and therefore protein 
based. However these protein based therapeutics have some disadvantages like 
production costs, susceptibility to proteolysis and, in case of monoclonal anti-
bodies, the necessity of intravenous access and the development of an immu-
nological response against the therapeutic antibody. These disadvantages can 
be overcome by using GAG based therapeutics, although chapter 5 reveals one 
of the major problems in GAG based therapy namely specificity. Other factors 
important in therapeutic application like bio distribution and type of chemical 
bonding are relatively comparable between glycans and protein based therapies. 
Concerning ligand specificity, GAGs are synthesized in the Golgi apparatus by po-
lymerization of the monosaccharide units and are subsequently sulfated by a 
number of enzymes. The degree of sulfation as well as the position of the sulfate 
groups determines the binding affinity for different ligands. Although a disaccha-
ride unit can be sulfated on the N-, 2O-, 3O- and 6O- positions, leading to a wide 
variety of GAGs, these polysaccharides are not produced to bind specifically one 
ligand, unlike antibodies. Antibodies are produced to target one epitope on a 
ligand and are negatively selected for cross reaction to auto antigens. This differ-
ence in synthesis process makes the glycan more prone to have affinity for mul-
tiple epitopes and therefore more prone to cross react and subsequently more 
prone to side effects, as seen in chapter 5. Nevertheless, glycan based therapy 
has major advances too, e.g. easy and cheap production, and relatively easy ad-
ministration, although subcutaneous injection is still needed. Decades of experi-
ence with heparin as anti-coagulant with relatively minor side effects, shows that 
GAG based therapy targeting inflammation should be considered a viable option. 
Besides leukocyte recruitment we also investigated the role of HSPGs in 
complement activation in this thesis. The current standings in the treatment of 
complement using GAGs were reviewed in chapter 6. Literature has shown that 
properdin, a positive regulator of the alternative pathway (AP), is an important 
mediator in proteinuria induced tubular epithelial damage (26,27). Subsequently 
our group revealed that under proteinuric conditions properdin bind to HSPGs 
on proximal tubular epithelial cells (PTECs). In these studies the epitope require-
ments for properdin interaction with HS was determined and it was shown that 
binding of properdin to PTECs was significantly different from binding to endo-
thelial cells (28,29). However, a study by Harboe and colleagues showed that 
on endothelial cells binding of properdin is dependent on the initial binding 
of C3b (30). In chapter 7 we convincingly showed that binding of properdin to 
PTECs is independent of prior C3b deposition and binding experiments with syn-
decan-1 knockout PTECs reveal that binding of properdin is largely dependent of 
syndecan-1. These results indicate that under proteinuric conditions, properdin 
binds to HSPGs on the surface of PTECs and initiates the formation of the alterna-
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proteinuria mediated tubular epithelial damage should be investigated. 
In chapter 7 we furthermore show that Salp20, a tick saliva protein, binds 
with high affinity to properdin, independent of initial C3b binding, prevents bind-
ing of properdin to HSPGs and can dose dependently inhibit the deposition of 
C3b on PTECs in vitro. The fact that both the binding of C3b and HSPG can be 
blocked by Salp20, suggests that C3b, HSPGs and Salp20 share the same binding 
epitope on properdin. However, delicate work by two separate groups showed 
that the epitopes on properdin for C3b and sulfated glycoconjugates are not 
the same but positioned close to each other. They showed that C3b and HSPG 
binding is dependent on the trombospondin-1 repeat 5 of properdin. However 
trypsin treatment of properdin resulted in an altered trombospondin-1 repeat 
5 and thereby abolished C3b binding while sulfated glycoconjugates still bound 
(31,32). Nevertheless it is interesting that Salp20 can inhibit both the binding of 
C3b and HSPGs to properdin and this bimodal inhibiting effect could be beneficial 
for developing an AP blocking agent for proteinuric patients. As discussed in the 
thesis introduction, many renal diseases are characterized by AP activation and 
therefore Salp20 mediated inhibition of properdin could be a viable target for 
treatment of AP mediated renal diseases. In OVA-induced asthma and elastase 
induced abdominal aortic aneurysm Salp20 has already demonstrated a reduc-
tion in AP activation and subsequent injury (33). If the immunogenicity of Salp20 
can be tackled, further research should be undertaken to evaluate the clinical 
potential of this powerful inhibitor.
In chapter 6 and 7 we discuss multiple interactions between GAGs and 
complement factors, and present literature that shows that heparin can bind a 
variety of complement factors with high affinity (34). To evaluate whether this 
interaction can be targeted using heparan sulfate/heparin derivatives, we tested 
a library of GAGs for their complement inhibiting potential in chapter 8. From 
the library of GAGs we could not identify a specific classical pathway (CP) or AP 
inhibitor. However, we demonstrated that small heparin- and heparan sulfate-de-
rived oligosaccharides specifically inhibit the lectin pathway (LP) of complement 
and that this is most likely by inhibition of the MASP enzymes. The direct effect 
of GAGs on the MASP enzymes should however be confirmed in experiments 
with recombinant MASP enzymes. Nevertheless it is an interesting finding since 
the LP has been identified as a contributor to several renal diseases like I/R and 
transplantation, but also diabetic nephropathy, as we have shown in chapter 3. 
Interestingly, inhibition of MASP-2 using monoclonal antibodies has been shown 
to reduce LP mediated experimental gastrointestinal I/R injury (35) and clinical 
phase II trials are now performed to evaluate the effect of these monoclonal 
antibodies in patients suffering from thrombotic microangiopathies. However, 
complete consensus is not yet reached on the exact mechanism by which the 
LP causes injury in I/R, either via the canonical LP activation pathway, or via a 
LP activation independent pathway. Doubt is raised by a delicate study showing 
that MBL can be internalized by tubular epithelial cells after reperfusion injury 
and display pro-inflammatory effects separate of LP activation (36). One could 
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speculate about the mechanism of internalization, but it could well be that the 
interaction between GAGs and the MBL/MASP complex is a mediator in the in-
ternalization process. 
MASP enzymes belong to the family of serine proteases. Interactions be-
tween GAGs and serine proteases (inhibitors) have long been known, of which 
the interaction with anti-thrombin III is most studied (37). Studies concerning 
the interaction of GAGs with anti-thrombin III indicate that a penta-saccharide 
is the smallest GAGs able to stimulate the effect of anti-thrombin (38). This 
suggests that the tetra-and hexa-saccharides tested in chapter 8 cannot inhib-
it anti-thrombin III. Whether this is the case, and whether the tested tetra-and 
hexa-saccharides can influence the function of other serine proteases (inhibitors) 
should be tested. Unfortunately our results in chapter 8 indicate that inhibition 
of the MASP enzymes requires relatively high concentrations of small heparin 
fragments, although affinity studies should be performed in surface plasmon res-
onance experiments to confirm this. Nevertheless, this indicates that it might be 
hard to achieve therapeutically sufficient plasma levels in clinical and experimen-
tal treatment. However we do show that it is possible to inhibit a specific com-
plement pathway using small GAGs with a reasonable affinity, which might form 
the basis for further development of small glycan-based specific MASP inhibitors.
Future perspectives
 Classic anti-inflammatory drugs like prednisolone are nonspecific inhibi-
tors of the immune system, inhibiting the activation of pro-inflammatory cellular 
pathways. This entails that they are powerful inhibitors and are usable in a wide 
variety of inflammation mediated diseases. The downsides to this however are 
the non-specific inhibition and multiple immunological and non-immunological 
side effects, predominantly on the long run. Therefore the need for new, more 
specific anti-inflammatory drugs is clear. In this thesis we targeted two distinct 
processes in inflammation namely cellular influx from the vascular system and 
proteinuria induced complement activation on renal tubular epithelium. We 
have shown like others that targeting the interaction of HS with inflammatory 
components is a promising way to reduce inflammation. We attempted to tar-
get this interaction using GAGs e.g. modified heparin derivatives. However we 
have only tested a small amount of the different GAGs available. Sources for 
GAGs can be animals, plants and bacteria, but semi-synthetic or fully-synthetic 
GAGs can also be produced. The GAGs derived from these sources have different 
characteristics and can be chemically modified to represent a specific length and 
sulfation pattern. These characteristics of GAGs can be very influential in their 
binding properties as can be seen in this thesis. The use of GAGs as a treatment 
for inflammation has a number of advantages since they are easy to produce and 
therefore cheap. Moreover, a lot of experience has been obtained with the use 
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GAG based treatments. However, as discussed in various chapters and above, a 
downside of GAG based treatment is the nonspecific binding of inflammatory 
mediator’s by GAGs. Although high affinity protein binding by GAGs has been 
shown before in the interaction between heparin and antithrombin III, affinity 
for inflammatory mediators is often in the micro molar range instead of the nano 
molar range like in protein based treatment, as demonstrated in this thesis.
 Based on this thesis and on literature it is fair to state that targeting the 
interaction between endo-and epithelial cells and chemokines, cytokines, com-
plement factors and lectins is a promising strategy to reduce inflammation. The 
down modulation of specific sulfotransferases and the use of GAG based ther-
apies in inflammation have potential. The finding that endothelial HSPGs play 
a role in the development of fibrosis has not been shown before. It would be 
interesting to unravel in which pro-fibrotic pathway the endothelial HSPGs are 
involved. Moreover treatment strategies targeting endothelial HSPG synthesis or 
sulfation could be tested in renal models for fibrosis. Targeting the chemokine/
HSPG interaction using fluid phase GAGs has been proven difficult , however oth-
er ways to target this interaction can be very interesting. Silencing RNA against 
sulfotransferases might reduce both the migration of leukocytes trough the vas-
cular endothelium, and might also influence the lymphatic migration, since this 
process is also reliant on the chemokine/HSPG interaction. This thesis also shows 
potential for small heparin fragments and Salp20 in treating LP and AP mediat-
ed diseases respectively. It would be interesting to study whether small heparin 
fragments can inhibit LP activation on cells and reduce LP mediated renal injury 
in e.g. experimental I/R. In case of Salp20 the focus should be on determining 
the properdin binding epitope and on constructing non immunogenic analogues, 
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